News

Model Grant Agreements Unit Cost and Lump Sum published

Published on | 4 years ago

Programmes
MSCA HorizonEU L+F

On the Funding&Tender Portal (reference documents) - 2 new Model Grant Agreements (MGA) for Horizon Europe have been published (besides the "general" MGA already available) :

  • The Unit MGA for HE, including
    • the MSCA specificities
    • provisions for ERA Fellowships which are similar with MSCA Post-Doctoral Fellowships (PF) the only difference being that the Fellows are called ‘ERA Fellows’ and not ‘MSCA fellows’
  • The Lump Sum MGA

The Annotated MGA has not yet been published and as explained in the MGA workshop of the R&I days (23.06.2021) this will be published in July in a fragmented way, with the aim that it is completely published by September.

 

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1864 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.